IndustryCompany release

Brainstorm Cell proposes governance reforms to settle NurOwn derivative suits, with $725,000 in fees

🇺🇸 Brainstorm Cell Therapeutics Inc. (BCLI) · Fri 20 Nov 2026

The ALS cell therapy developer, as nominal defendant, has signed a stipulation to resolve stockholder suits over statements on FDA concerns about NurOwn; the deal needs court approval.

Brainstorm Cell Therapeutics has signed a stipulation, dated 2 November 2026, to settle a group of stockholder derivative proceedings tied to its NurOwn programme for amyotrophic lateral sclerosis (ALS). The company is a nominal defendant in the cases, meaning any claims are brought on its behalf against current and former officers and directors.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Brainstorm Cell Therapeutics Inc. ↗

Article written by VigiEye from the official source (Brainstorm Cell Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →